# Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Source: https://onco.cc/trials/nct07516093/  
OnCo record `nct07516093` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Bexobrutideg in chronic lymphocytic leukaemia, now recruiting.

## Summary

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL is a phase 3 interventional study registered as NCT07516093, led by Nurix Therapeutics, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL). Planned enrolment is 620 participants (estimated). The study started in 2026-08-03 and primary completion is expected in 2029-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07516093
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sponsor: Nurix Therapeutics
- Enrolled: 620

## Sources

- ClinicalTrials.gov NCT07516093: https://clinicaltrials.gov/study/NCT07516093

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/)
- drugs: [Bexobrutideg](https://onco.cc/drugs/bexobrutideg/)
- companies: [Nurix Therapeutics](https://onco.cc/companies/nurix/)

---
JSON: https://onco.cc/api/v1/entities/nct07516093.json